Y-Biologics, Inc. (KOSDAQ:338840)
South Korea
· Delayed Price · Currency is KRW 26,150
-2,000 (-7.10%)
At close: Dec 5, 2025
Y-Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | -8,735 | -6,442 | -20,871 | -18,804 | -17,071 | -10,029 | Upgrade
|
| Depreciation & Amortization | 1,905 | 2,038 | 2,354 | 2,962 | 2,316 | 1,469 | Upgrade
|
| Loss (Gain) From Sale of Assets | 15.62 | 0 | -329.65 | 172.61 | -15.23 | - | Upgrade
|
| Stock-Based Compensation | 474.64 | 1,189 | 2,097 | 2,607 | 1,570 | 1,169 | Upgrade
|
| Provision & Write-off of Bad Debts | 174.63 | 300.68 | - | 425.54 | - | - | Upgrade
|
| Other Operating Activities | 667.18 | -1,486 | 10,736 | 207.98 | -331.6 | 2,144 | Upgrade
|
| Change in Accounts Receivable | 3.85 | 233.33 | 116.51 | -290.23 | -577.53 | -245.68 | Upgrade
|
| Change in Accounts Payable | -17.94 | 2.02 | 1.21 | - | - | - | Upgrade
|
| Change in Unearned Revenue | - | - | - | 41.03 | - | - | Upgrade
|
| Change in Income Taxes | -241.22 | - | -84.38 | 84.38 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 496.83 | 21.86 | -1,627 | 2,490 | 4,941 | -5,476 | Upgrade
|
| Operating Cash Flow | -5,257 | -4,143 | -7,607 | -10,105 | -9,168 | -10,968 | Upgrade
|
| Capital Expenditures | -463 | -2,860 | -193.42 | -1,088 | -7,552 | -777.69 | Upgrade
|
| Sale of Property, Plant & Equipment | 6.68 | - | 963.98 | 237.65 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -200 | - | -2.72 | -9.07 | -18.61 | -165.15 | Upgrade
|
| Investment in Securities | -31,645 | -2,750 | -250 | - | - | - | Upgrade
|
| Other Investing Activities | -166.02 | 187.84 | 3,197 | 100.51 | -325.43 | -65.22 | Upgrade
|
| Investing Cash Flow | -32,467 | -5,422 | 3,715 | -759.15 | -7,896 | -998.06 | Upgrade
|
| Long-Term Debt Issued | - | - | 500 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -2,000 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -193.97 | -2,781 | -803.57 | -356.89 | -275.35 | Upgrade
|
| Total Debt Repaid | -651.99 | -2,194 | -2,781 | -803.57 | -356.89 | -275.35 | Upgrade
|
| Net Debt Issued (Repaid) | 34,348 | -2,194 | -2,281 | -803.57 | -356.89 | -275.35 | Upgrade
|
| Issuance of Common Stock | 131.63 | 201.23 | 14,063 | 49.52 | 604.89 | 20,163 | Upgrade
|
| Other Financing Activities | -0 | 65 | -0 | -0 | -0 | - | Upgrade
|
| Financing Cash Flow | 34,480 | -1,928 | 11,782 | 6,896 | 247.99 | 19,888 | Upgrade
|
| Foreign Exchange Rate Adjustments | 18.91 | 40.24 | 32.59 | -290.95 | 300.15 | -49.7 | Upgrade
|
| Net Cash Flow | -3,225 | -11,452 | 7,922 | -4,259 | -16,516 | 7,872 | Upgrade
|
| Free Cash Flow | -5,720 | -7,003 | -7,801 | -11,193 | -16,720 | -11,745 | Upgrade
|
| Free Cash Flow Margin | -158.36% | -121.52% | -224.21% | -269.68% | -344.94% | -174.48% | Upgrade
|
| Free Cash Flow Per Share | -385.09 | -468.82 | -623.04 | -910.72 | -1374.20 | -1177.03 | Upgrade
|
| Cash Interest Paid | 401.13 | 51.43 | 142.22 | 95.56 | 88.47 | 128 | Upgrade
|
| Cash Income Tax Paid | - | 61.62 | 2.89 | -7.34 | 4.1 | -61.45 | Upgrade
|
| Levered Free Cash Flow | 12,481 | -5,270 | -5,629 | -7,303 | -20,134 | -15,151 | Upgrade
|
| Unlevered Free Cash Flow | 12,721 | -5,243 | -5,539 | -7,238 | -20,062 | -14,872 | Upgrade
|
| Change in Working Capital | 241.52 | 257.21 | -1,593 | 2,325 | 4,364 | -5,721 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.